BGLC
BGLC
NASDAQ · Trading Companies & Distributors

Bionexus Gene Lab Corp

$1.64
+0.09 (+5.81%)
Financial Highlights (FY 2026)
Revenue
10.03M
Net Income
-4,033,394
Gross Margin
14.6%
Profit Margin
-40.2%
Rev Growth
-12.1%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 14.6% 14.6% 60.4% 60.4%
Operating Margin -39.9% -35.9% 8.4% 8.8%
Profit Margin -40.2% -38.2% 9.4% 7.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 10.03M 11.41M 1.58M 1.38M
Gross Profit 1.47M 1.67M 956.1K 835.6K
Operating Income -4,006,548 -4,101,800 133.2K 121.1K
Net Income -4,033,394 -4,129,285 149.1K 96.1K
Gross Margin 14.6% 14.6% 60.4% 60.4%
Operating Margin -39.9% -35.9% 8.4% 8.8%
Profit Margin -40.2% -38.2% 9.4% 7.0%
Rev Growth -12.1% -12.1% +23.5% +22.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 748.7K 864.2K
Total Equity 3.20M 3.19M
D/E Ratio 0.23 0.27
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -3,855,749 -4,166,717 198.9K 172.0K
Free Cash Flow 98.9K 88.8K